RxDoctor Payments Data

Steven Cohen, MD

Family Medicine · McConnellsburg, PANPI 1083780407

Payments from drug & device makers

$741in general payments, 2019–2025

Across 15 payments — averaging $49.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$194
  • AstraZeneca$183
  • Johnson & Johnson$147
  • Novo Nordisk$120
  • Boehringer Ingelheim$65
  • Merck$16
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$73199%
  • Education$101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie3$194
AstraZeneca3$183
Johnson & Johnson5$147
Novo Nordisk1$120
Boehringer Ingelheim1$65
Merck1$16
Amgen1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$741 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$56,721
Medicare patients
53
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone40$29,770
XareltoRivaroxaban32$26,345
RybelsusSemaglutide23$22,343
EliquisApixaban25$17,250
JardianceEmpagliflozin25$16,585
FarxigaDapagliflozin Propanediol22$13,850
Breo ElliptaFluticasone/Vilanterol20$9,852
EntrestoSacubitril/Valsartan14$8,501
Combivent RespimatIpratropium/Albuterol Sulfate13$8,188
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,419
JanuviaSitagliptin Phosphate13$6,764
Albuterol Sulfate HfaAlbuterol Sulfate30$1,943
Diclofenac Sodium32$1,891
SynthroidLevothyroxine Sodium28$1,408
Atorvastatin Calcium160$1,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$147$26,34532 claims
Boehringer IngelheimJardiance, Combivent Respimat$65$24,77338 claims
Novo NordiskRybelsus$120$22,34323 claims
AstraZenecaFarxiga, Breztri Aerosphere$183$21,27034 claims
MerckJanuvia$16$6,76413 claims
AbbVieSynthroid$194$1,40828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in McConnellsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →